Clinical Trial Update: A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD) [Phase 3]

View source ↗

Summary

Phase 3 study results for the BTK inhibitor ibrutinib in chronic graft-versus-host disease have been posted following completion of the trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Graft vs Host Disease | Phase 3 | Status: COMPLETED | Results posted: 2023-02-03